001360 — Samsung Pharm Co Income Statement
0.000.00%
Last trade - 00:00- KR₩141bn
- KR₩136bn
- KR₩44bn
Annual income statement for Samsung Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 48,269 | 54,901 | 51,832 | 51,955 | 44,294 |
| Cost of Revenue | |||||
| Gross Profit | 10,451 | 9,282 | 24,619 | 22,973 | 19,774 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 66,803 | 75,487 | 75,379 | 78,035 | 60,363 |
| Operating Profit | -18,534 | -20,586 | -23,547 | -26,080 | -16,069 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -39,877 | -40,276 | -25,093 | -23,675 | -14,092 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -39,877 | -40,276 | -25,093 | -24,812 | -14,092 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -39,877 | -40,276 | -25,093 | -24,812 | -14,092 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -39,877 | -40,276 | -25,093 | -24,812 | -14,092 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -464 | -494 | -210 | -264 | -143 |
| Dividends per Share |